Animals Adult wild-type male C57BL/6 N mice were purchased from Orient Bio (Sungnam, South Korea)
In this article, GoodRx, a platform for medication savings, takes a look at the current state of GLP-1 patient experience
In the SURPASS program for type 2 diabetes, tirzepatide demonstrated A1C reductions of 2.07-2.59% across doses, with up to 97% of participants achieving A1C below 7.0%
These medications mimic the natural actions of GLP-1, improving insulin secretion, enhancing glucose management, and promoting weight loss in patients with type 2 diabetes or obesity
There is no quick solve for increasing widespread access to GLP-1s for other indications
*****By using this website and sending us your information, you are giving us permission to contact you by electronic and non-electronic means